近年來，隨著經濟的不斷發展與繁榮，民眾的生活品質和水準越來越提高，政府日趨重視生技產業的發展，特別是對於免疫細胞產業的注意度逐年地上升。政府相繼地推出了相關的政策，證實了政府對於免疫細胞產業的大力重視，免疫細胞產業也將會進入快速的發展時期。P個案公司多年來在免疫細胞成果轉化方面取得了突出的成績。P個案公司具備比較強的技術研發能力，從而形成了在免疫細胞產業的競爭門檻與競爭優勢。
然而目前P個案公司的發展面臨重大轉型期，必須做改革，以適應發展的需求。本研究為實務導向，詳述了P個案公司發展過程之中的問題，並提出因應的解決方案，制定P個案公司的發展策略，從而提高P個案公司的營運水準，推動P個案公司的長遠發展。
本研究首先對公司策略的相關理論做了回顧，從理論的角度引出對於P個案公司現況的研究。隨後，本研究藉用五力分析法對企業的外部環境做整體性的分析，研究發現P個案公司所處的產業有諸多的發展機會，也面臨相當程度的挑戰，P個案公司必須靈活地把握。之後運用SWOT分析分別指出了P個案公司的優勢、劣勢、機會與威脅，發現P個案公司在該產業具有比較大的競爭優勢，並相應地提出了P個案公司的發展策略。本研究有助於P個案公司提高對於本身所處環境以及經營方式的認識，充分地發揮競爭優勢，彌補本身的缺點，提高本身的經營能力，並最終實現P個案公司的永續發展。

In recent years, with the continuous development and prosperity of the economy, the quality and standard of life of the people have been increasing, and the government has paid more and more attention to the development of the biotechnology industry, the attention to the immune cell industry has been increasing year by year especially. The government has introduced relevant policies one after another, which proves that the government attaches great importance to the immune cell industry, and the immune cell industry will also enter a period of rapid development. P Case Company has made outstanding achievements in the transformation of immune cell achievements over the years. The P case company has strong technology research and development capabilities relatively, thus forming a competitive threshold and competitive advantage in the immune cell industry.
However, the development of P Case Company is facing a major transformation period currently, and reforms must be made to meet the needs of development. This study is practice-oriented, and details the problems in the development process of P case company, and proposes corresponding solutions, and formulates the development strategy of P case company, so as to improve the operation level of P case company and promote the long-term development of P case company .
This study first reviews the relevant theories of corporate strategy, and draws out the conclusions about the current situation of the company in case P from a theoretical perspective. this study used the Five Forces analysis method to conduct a holistic analysis of the external environment of the enterprise Subsequently. The study found that the industry in which P case company is located has many development opportunities and also faces considerable challenges. P case company must grasp flexibly. Then use the SWOT analysis to point out the advantages, disadvantages, opportunities and threats of P case company respectively, find that P case company has a large competitive advantage in this industry relatively, and put forward the development strategy of P case company accordingly. This study will help P case company to improve its understanding of its own environment and operating methods, give full play to its competitive advantages, make up for its own shortcomings, improve its own management capabilities, and realize the sustainable development of P case company finally.

論文審定書 i
誌　謝 ii
摘　要 iv
Abstract v
目　錄 vii
圖　次 ix
表　次 x
第一章　緒論 1
第一節　研究背景 1
第二節　研究動機 5
第三節　研究問題與目的 6
第二章　產業現況及文獻探討 7
第一節　免疫細胞療法及產業現況 7
第二節　衛服部細胞治療特管法相關資訊 13
第三節　波特五力分析模型 14
第四節　SWOT分析法 15
第五節　商業模式:九宮格商業模式 16
第三章　研究方法 17
第一節　研究架構 17
第二節　個案公司簡介 17
第三節　研究設計與方法 23
第四章　資料分析 27
第一節　個案公司之SWOT分析 27
第二節　個案公司之SWOT策略組合模型 29
第三節　個案公司產業環境之五力分析 32
第四節　個案公司商業模式之九宮格分析 34
第五節　競爭策略 36
第五章　結論與建議 40
第一節　研究發現與建議 40
第二節　研究建議 43
第三節　研究限制與後續研究發展 44
參考文獻 45
附錄　訪談紀錄(受訪者回答) 46

1.Barbuto J A,Ensina L F,Neves AＲ (2004).Dendritic cell-tumor
cell hybrid vaccination for metastatic cancer. Cancer Immunology
Immunotherapy,53(12):1111-1118.
2.Kantoff P W,Higano C S,Shore N D (2010).Sipuleucel-T immunotherapy for castration-resistant prostate cancer.New England Journal of Medicine,363(5):411-422.
3.Kershaw M H,Westwood J A,Parker L L (2006).A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clinical Cancer Ｒesearch,12(20):6106-6115.
4.Kumar C,Kohli S,Chiliveru S (2017).A retrospective analysis comparing APCEDEN dendritic cell immunotherapy with best supportive care in refractory cancer.Immunotherapy,9(11):889-897.
5.Osterwalder A,, Pigneur Y. (2010), Business Model Generation is a handbook for visionaries, game changers, and challengers , John Wiley & Sons, Inc.
6.Park JＲ,Digiusto D L,Slovak M (2007).Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with Neuroblastoma,Molecular Therapy,15(4):825-833.
7.Porter D L,Levine B L,Kalos M (2011).Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.New England Journal of Medicine,365(8):725-733.
8. Porter,M.(1980). Industry Structure and Competitive Strategy: Keys to Profitability. Financial analysts journal ,Volume 36, Issue 4.
9.Porter, M.E. (1980), “Clusters and the New Economics of Competition,” Harvard Business Review,76 (6), 77-90.